Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy

M. I. Koukourakis, L. Corti, J. Skarlatos, A. Giatromanolaki, B. Krammer, S. Blandamura, M. Piazza, T. Verwanger, G. Schnitzhofer, J. Kostandelos, K. Beroukas

Research output: Contribution to journalArticle

Abstract

Purpose: The role of apoptosis related proteins in the response of human malignancies to photodynamic therapy (PDT) is under investigation. The aim of the study was to examine the role of p53 and of bcl-2 protein expression in the response to PDT. Materials and Methods: Paraffin-embedded material from 37 patients with early esophageal cancer treated with PDT (argon dye laser after intravenous injection of hematoporphyrine derivative) was studied immunohistochemically for p53 protein nuclear accumulation and bcl-2 cytoplasmic expression. Patients with residual disease after two rounds of PDT received definitive radiotherapy. In a subsequent in vitro study, W138 human lung fibroblasts and W138-SV-40 virus transformed were assessed for their sensitivity to PDT. The constitutive bcl-2 overexpression of the transformed cells vs. normal cells (assessed with RT-PCR) was 16-fold. Results: Positive bcl-2 and p53 expression was noted in 10 out of 36 (27%) and 14 out of 36 (39%) patients, respectively. Seven out of 11 tumors (63%) with bcl-2 expression responded completely to PDT vs. 6 out of 26 (23%) of cases with no bcl-2 expression (p=0.02). No association of p53, T-stage and of histology grade with response to PDT or PDT/RT was noted. The sensitivity to PDT of transformed human fibroblasts compared to normal ones was 4 times more at a fluence of 4.3 J/cm 2 (4% vs. 1% cell kill) as well as at a fluence of 5.4 J/cm 2 (8% vs. 2% cell kill). Conclusion: Bcl-2 protein expression is associated with favorable response to PDT and can be used as a predictor of cancer response to PDT. This finding can be explained by experimental studies showing that PDT induces selective degradation of the bcl-2 protein, leading to apoptosis by decreasing the bcl-2/bax ratio. Studies on PDT combination with agents targeting bcl-2 (i.e. taxanes) are on going to eventually assess a super-additive effect.

Original languageEnglish
Pages (from-to)663-668
Number of pages6
JournalAnticancer Research
Volume21
Issue number1 B
Publication statusPublished - 2001

Keywords

  • Bcl-2 and p53
  • Esophageal cancer
  • Photodynamic therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy'. Together they form a unique fingerprint.

  • Cite this

    Koukourakis, M. I., Corti, L., Skarlatos, J., Giatromanolaki, A., Krammer, B., Blandamura, S., Piazza, M., Verwanger, T., Schnitzhofer, G., Kostandelos, J., & Beroukas, K. (2001). Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy. Anticancer Research, 21(1 B), 663-668.